The rise of copyright’s drug initially fueled significant expansion in the drug sector, generating a perception of substantial profits. However, placing capital in companies primarily reliant on flagship drugs like Viagra presents considerable dangers. Exclusive rights expiration has resulted in

The recent surge in funding into niche pharmaceutical companies, particularly those focusing on experimental therapies and complex drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the potential for revolutionary treatments and significant returns is cer